• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于白杨素的 CDK9 PROTACs 的发现及其抗肿瘤活性。

Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.

机构信息

State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China.

State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China.

出版信息

Bioorg Chem. 2018 Dec;81:373-381. doi: 10.1016/j.bioorg.2018.08.028. Epub 2018 Aug 30.

DOI:10.1016/j.bioorg.2018.08.028
PMID:30196207
Abstract

Wogonin is a natural product isolated from the Scutellaria baicalensis and has been proved to be a potent and selective inhibitor of CDK9. Using this scaffold, we designed and synthesized a series of proteolysis targeting chimeras (PROTACs) targeting CDK9 by recruiting ubiquitin E3 ligase cereblon (CRBN). For constructing diverse Wogonin-based PROTACs, a "click chemistry" approach was employed for the synthesis of CDK9-targeting PROTACs. The results of western blotting assays showed that compounds containing triazole group in the linker could selectively downregulate the intracellular CDK9 level. Among these compounds, 11c could selectively degrade CDK9 in a concentration-dependent manner. In addition, the application of the proteasome inhibitor MG132 and CRBN siRNA silencing confirmed that 11c could promote the proteasome-dependent and CRBN-dependent degradation. Consistent with the degradation of the CDK9 protein, 11c selectively inhibits proliferation of CDK9-overexpressed cancer cells. Thus, our Wogonin-based PROTAC would be an efficient probe that induces the degradation of CDK9.

摘要

汉黄芩素是从黄芩中分离得到的天然产物,已被证明是一种有效的、选择性的 CDK9 抑制剂。我们利用这个支架,通过招募泛素 E3 连接酶 cereblon (CRBN),设计并合成了一系列针对 CDK9 的蛋白水解靶向嵌合体 (PROTACs)。为了构建不同的基于汉黄芩素的 PROTACs,我们采用“点击化学”方法合成了针对 CDK9 的 PROTACs。Western blot 检测结果表明,连接子中含有三唑基团的化合物可以选择性地下调细胞内 CDK9 水平。在这些化合物中,11c 可以以浓度依赖的方式选择性地降解 CDK9。此外,蛋白酶体抑制剂 MG132 和 CRBN siRNA 沉默的应用证实,11c 可以促进蛋白酶体依赖和 CRBN 依赖的降解。与 CDK9 蛋白的降解一致,11c 选择性地抑制 CDK9 过表达的癌细胞的增殖。因此,我们基于汉黄芩素的 PROTAC 将是一种有效的诱导 CDK9 降解的探针。

相似文献

1
Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.基于白杨素的 CDK9 PROTACs 的发现及其抗肿瘤活性。
Bioorg Chem. 2018 Dec;81:373-381. doi: 10.1016/j.bioorg.2018.08.028. Epub 2018 Aug 30.
2
Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.基于汉黄芩素的选择性细胞周期蛋白依赖性激酶 9(CDK9)抑制剂的设计及其在体外和体内抗肿瘤活性。
Eur J Med Chem. 2019 Sep 15;178:782-801. doi: 10.1016/j.ejmech.2019.06.024. Epub 2019 Jun 15.
3
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.CDK9 抑制剂的生物学和药物化学研究进展:最新综述。
J Med Chem. 2020 Nov 25;63(22):13228-13257. doi: 10.1021/acs.jmedchem.0c00744. Epub 2020 Sep 17.
4
Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.白杨素和相关的天然类黄酮是 CDK9 的抑制剂,通过转录抑制 Mcl-1 诱导癌细胞凋亡。
Cell Death Dis. 2011 Jul 21;2(7):e182. doi: 10.1038/cddis.2011.66.
5
Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity.设计并合成新型咪唑并[4,5-b]吡啶类化合物作为具有 CDK9 抑制活性的强效抗癌剂。
Bioorg Chem. 2018 Oct;80:565-576. doi: 10.1016/j.bioorg.2018.07.006. Epub 2018 Jul 6.
6
CDK9 targeting PROTAC L055 inhibits ERα-positive breast cancer.靶向 CDK9 的 PROTAC L055 抑制 ERα 阳性乳腺癌。
Biomed Pharmacother. 2024 Aug;177:116972. doi: 10.1016/j.biopha.2024.116972. Epub 2024 Jun 21.
7
Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.基于氨基吡唑的 CDK9 PROTAC 使胰腺癌细胞对 venetoclax 敏感。
Bioorg Med Chem Lett. 2021 Jul 1;43:128061. doi: 10.1016/j.bmcl.2021.128061. Epub 2021 Apr 23.
8
Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.发现香豆素衍生物具有强效和选择性细胞周期蛋白依赖性激酶 9(CDK9)抑制作用,具有高抗肿瘤活性。
Eur J Med Chem. 2020 Aug 15;200:112424. doi: 10.1016/j.ejmech.2020.112424. Epub 2020 May 15.
9
Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro.发现并合成具有强效抗肿瘤活性的新型汉黄芩素衍生物。
Eur J Med Chem. 2017 Nov 10;140:421-434. doi: 10.1016/j.ejmech.2017.09.046. Epub 2017 Sep 22.
10
Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.基于金纳米粒子的多头蛋白水解靶向嵌合体靶向降解间变性淋巴瘤激酶。
Colloids Surf B Biointerfaces. 2020 Apr;188:110795. doi: 10.1016/j.colsurfb.2020.110795. Epub 2020 Jan 13.

引用本文的文献

1
Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs.基于 Cereblon 的 PROTAC 的合成、生物学评价及临床试验
Commun Chem. 2025 Jul 29;8(1):218. doi: 10.1038/s42004-025-01598-9.
2
Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues.癌症治疗中靶向细胞周期蛋白依赖性激酶:蛋白水解靶向嵌合体和分子胶的进展
NPJ Precis Oncol. 2025 Jun 28;9(1):204. doi: 10.1038/s41698-025-00931-8.
3
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer.PROTAC 降解的细胞周期蛋白依赖性激酶在乳腺癌治疗中的研究进展
Breast Cancer (Dove Med Press). 2025 Jun 13;17:511-521. doi: 10.2147/BCTT.S527906. eCollection 2025.
4
First ATG101-recruiting small molecule degrader for selective CDK9 degradation autophagy-lysosome pathway.首个用于选择性降解CDK9的ATG101招募型小分子降解剂 自噬-溶酶体途径
Acta Pharm Sin B. 2025 May;15(5):2612-2624. doi: 10.1016/j.apsb.2025.03.047. Epub 2025 Apr 4.
5
Targeted degradation of CDK9 potently disrupts the MYC-regulated network.CDK9的靶向降解有力地破坏了MYC调控的网络。
Cell Chem Biol. 2025 Apr 17;32(4):542-555.e10. doi: 10.1016/j.chembiol.2025.03.001. Epub 2025 Mar 27.
6
Characteristic roadmap of linker governs the rational design of PROTACs.连接子的特征路线图决定了PROTACs的合理设计。
Acta Pharm Sin B. 2024 Oct;14(10):4266-4295. doi: 10.1016/j.apsb.2024.04.007. Epub 2024 Apr 11.
7
PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras.蛋白水解靶向嵌合体(PROTAC)超越癌症——探索靶向蛋白降解治疗的新潜力。
Curr Top Med Chem. 2024;24(23):2050-2073. doi: 10.2174/0115680266309968240621072550.
8
PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives.PROTACs 在卵巢癌中的应用:现状与展望。
Int J Mol Sci. 2024 May 7;25(10):5067. doi: 10.3390/ijms25105067.
9
Biology of Pellino1: a potential therapeutic target for inflammation in diseases and cancers.Pellino1 的生物学:疾病和癌症炎症的潜在治疗靶点。
Front Immunol. 2023 Dec 18;14:1292022. doi: 10.3389/fimmu.2023.1292022. eCollection 2023.
10
Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development.革新药物靶向策略:在PROTAC开发中整合人工智能与基于结构的方法
Pharmaceuticals (Basel). 2023 Nov 24;16(12):1649. doi: 10.3390/ph16121649.